Yes, this pretty much ends the conjecture. This was a very large trial and the Data Safety Monitoring Board found it necessary to communicate preliminary results because of clinical importance. The full press statement is here: https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf and it's pretty darn clear. Of course this won't satisfy all of the hydroxycholorquine fans who may argue that the right level of zinc or azithromycin wasn't used.
I am sure that the reactions to this new article isn’t going to be limited to the question of the doses.
I can anticipate at least two other significant challenges:
- in both populations the level of mortality is around 25%, which indicates that patients were probably at an advanced stage of the disease and/or could not be treated the right way, possibly due to the high load of hospitals in UK at the time. Either way, this rate is much higher than what was reported elsewhere. Raoult reports 0.5% for instance
- the hydrochloriquine was not used in combination with the azithromycin if my understanding is correct.
So the protocole whose inefficiency is convincingly demonstrated appears to differ significantly from that said by Raoult to work, even if they both utilize the hydrochloriquine.
I am not a fan of any particular treatment, just trying to point out some questions.
Finally, I sense that momentum is building due to the accumulation of apparent data points against the hydrochloriquine, something akin to “there is no smoke without fire”, but I would just like to stress that both recently withdrawn article should be 100% removed from the picture since they demonstrated nothing at all.
Cheers,
Bernard